292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

In this episode, the hosts discuss the debate over Vertex Pharmaceuticals' novel pain drug and its clinical trial results. They also touch upon the farewell to the drug Aduhelm, Biogen's decision to give back the rights to the treatment, and the retirement of an FDA icon. The chapter explores the controversies surrounding the drug VX 548 in pain management, including addiction concerns and market reactions. The episode concludes with discussions on an influential FDA figure's experiences and the changing dynamics in the industry.